EXPLORE FMR: Early Feasibility Study of the PLAR Implant and Delivery System to Treat Functional Mitral Regurgitation

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPolares Medical SA

About this trial

An early feasibility study to evaluate the safety and feasibility of the PLAR Implant and Delivery System to treat severe functional mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. The study is a single-arm registry with the last follow-up visit at 5 years post-intervention. The study will enroll up to 10 patients at one (1) center in Brazil.

Eligibility criteria

Qualifiers

18 years of age or older

Greater than moderate functional mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure

Patient must present with an STS Score less than 10%

High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure

Disqualifiers

Severe tricuspid regurgitation

Severe aortic stenosis or insufficiency

Severe mitral annulus calcification

Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification

Trial design

Treatments tested in this trial

  • Transcatheter mitral valve repair (PLAR Implant and Delivery System)

Treatment groups

10 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Polares Medical SA

Lead sponsor

Polares Medical, Inc.

Collaborator